MX2008011872A - Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. - Google Patents

Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.

Info

Publication number
MX2008011872A
MX2008011872A MX2008011872A MX2008011872A MX2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A
Authority
MX
Mexico
Prior art keywords
hypertension
treatment
lowering lipids
thiazolidinedione analogues
thiazolidinedione
Prior art date
Application number
MX2008011872A
Other languages
English (en)
Inventor
Rolf F Kletzien
Gerard R Colca
Original Assignee
Metabolic Solutions Dev Compan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Compan filed Critical Metabolic Solutions Dev Compan
Publication of MX2008011872A publication Critical patent/MX2008011872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con análogos de tiazolidinediona que son útiles para tratar la hipertensión.
MX2008011872A 2006-03-16 2007-03-14 Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. MX2008011872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78278706P 2006-03-16 2006-03-16
PCT/US2007/006385 WO2007109037A2 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids

Publications (1)

Publication Number Publication Date
MX2008011872A true MX2008011872A (es) 2009-02-10

Family

ID=38433001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011872A MX2008011872A (es) 2006-03-16 2007-03-14 Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.

Country Status (11)

Country Link
US (1) US8629159B2 (es)
EP (1) EP2001469B1 (es)
JP (2) JP5149271B2 (es)
CN (1) CN101454006B (es)
AU (1) AU2007227594B2 (es)
CA (1) CA2646149A1 (es)
ES (1) ES2388555T3 (es)
MX (1) MX2008011872A (es)
NZ (1) NZ571870A (es)
PL (1) PL2001469T3 (es)
WO (1) WO2007109037A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
WO2007109088A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
PL2902026T3 (pl) 2006-03-16 2018-03-30 Metabolic Solutions Development Company Llc Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
KR101537830B1 (ko) * 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
KR20120103711A (ko) * 2009-12-15 2012-09-19 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 신경퇴행성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
WO2011084453A1 (en) 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
CN103153972A (zh) * 2010-04-19 2013-06-12 新陈代谢解决方案开发公司 噻唑烷二酮化合物的新的合成方法
DK2560956T3 (en) * 2010-04-19 2017-01-23 Octeta Therapeutics Llc Hitherto UNKNOWN SYNTHESIS OF THIAZOLIDE INDION COMPOUNDS
WO2012021476A1 (en) 2010-08-10 2012-02-16 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
CN102370984B (zh) * 2010-08-18 2015-04-08 天津金耀集团有限公司 以依普利酮和糖皮质激素为活性成分的吸入药物组合物
CN109400502A (zh) 2013-07-22 2019-03-01 新陈代谢解决方案开发公司 用于治疗代谢疾病的ppar-节制性化合物
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
CZ196693A3 (en) * 1991-04-11 1994-05-18 Upjohn Co Thiazolidinedione derivatives, and process for preparing thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
AU2002311057A1 (en) 2001-04-26 2002-11-11 Leciva, A.S. Method for obtaining pioglitazone as an antidiabetic agent
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
ITFI20030058A1 (it) 2003-03-06 2004-09-07 Univ Firenze Formulazioni farmaceutiche contenenti tiazolidinedioni
PL2902026T3 (pl) 2006-03-16 2018-03-30 Metabolic Solutions Development Company Llc Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
WO2007109088A2 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
KR101537830B1 (ko) 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체

Also Published As

Publication number Publication date
US8629159B2 (en) 2014-01-14
EP2001469B1 (en) 2012-05-23
JP5149271B2 (ja) 2013-02-20
NZ571870A (en) 2011-07-29
WO2007109037A2 (en) 2007-09-27
EP2001469A2 (en) 2008-12-17
CN101454006B (zh) 2012-12-26
PL2001469T3 (pl) 2012-10-31
JP2012251001A (ja) 2012-12-20
AU2007227594A1 (en) 2007-09-27
JP2009530286A (ja) 2009-08-27
ES2388555T3 (es) 2012-10-16
US20090137638A1 (en) 2009-05-28
WO2007109037A3 (en) 2007-11-08
CN101454006A (zh) 2009-06-10
AU2007227594B2 (en) 2012-11-15
CA2646149A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
HK1146484A1 (en) Thiazolidinedione analogues for the treatment of hypertension
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
WO2007092622A3 (en) Compositions and methods for treating bone
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
MX2010007490A (es) Preparacion de derivados de sulfamida.
ZA200900388B (en) Compositions and methods for the treatment of mucositis
SG155163A1 (en) Pharmacokinetically improved compounds
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IN2012DN02624A (es)
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
WO2007109088A3 (en) Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists

Legal Events

Date Code Title Description
FG Grant or registration